Single-dose HPV vaccination is increasingly supported by randomized evidence and global policy shifts.
I remember when HPV vaccination meant organizing three clinic visits for every patient. Each visit was another hurdle between a young person and long-term protection against HPV-related cancers. For years, multi-dose schedules reflected the best available evidence. But over the last decade, stronger data have emerged suggesting that one dose can provide protection against HPV16/18 infection that is comparable to two doses in adolescents.
Single-Dose HPV Vaccination Is Biologically Plausible
HPV vaccines generate strong immune responses because they use virus-like particles that efficiently prime immune memory.
Early schedules were designed conservatively because long-term effectiveness data were limited. Over time, trials and follow-up studies have shown that immune protection can persist even as antibody levels decline, meaning antibody titers alone are not a perfect proxy for clinical protection.
Randomized Trial Data Support Noninferior Protection With One Dose
A large randomized noninferiority trial found one dose was noninferior to two doses for preventing HPV16/18 infection over five years.
In the ESCUDDO efficacy trial (girls ages 12–16), one dose of either a bivalent or nonavalent HPV vaccine was noninferior to two doses for the primary endpoint (new HPV16/18 infections from months 12–60 persisting ≥6 months). Vaccine effectiveness was reported as at least 97% in each trial group.
Modeling Suggests One Dose Could Increase Population Impact Through Higher Coverage
Mathematical modeling indicates one-dose programs could avert most of the cancers prevented by two-dose programs if protection lasts long enough.
A modeling analysis in low and middle income country settings found that one-dose routine vaccination could avert most of the cervical cancers averted with two doses under assumptions of sufficient duration of protection, while using fewer total doses (improving efficiency and feasibility).
Global Policy Has Already Shifted Toward One or Two Doses
WHO has endorsed one- or two-dose schedules for most adolescents and young women, while recommending more doses for immunocompromised individuals.
WHO communications in 2022 describe SAGE-supported updates endorsing one- or two-dose schedules for most adolescent girls and young women, with three doses (or at least two) for immunocompromised people, including those living with HIV.
U.S. Guidance Is Currently Internally Inconsistent Across Federal Pages
CDC’s clinician schedule page still lists 2- and 3-dose schedules, while separate federal communications describe a January 2026 one-dose recommendation change.
- CDC’s clinician-facing “HPV Vaccination Recommendations” page continues to state: 2 doses before age 15; 3 doses if starting at 15–26 or immunocompromised.
- Meanwhile, a federal fact sheet and a CDC newsroom release describe an update adopted on Jan 5, 2026, including a one-dose HPV recommendation as part of a broader schedule overhaul.
Single-Dose Implementation Could Improve Access, Cost, and Completion
Fewer required visits may reduce drop-off and improve real-world program performance.
If one dose is adopted in more settings, likely benefits include improved completion, lower program costs, and simpler patient messaging, especially in settings where follow-up appointments are a major barrier.
Uncertainty Remains Around Very Long-Term Durability and Specific Populations
Long-term durability beyond a decade and performance in immunocompromised groups remain key research and policy considerations.
Even with strong 5-year randomized data, important questions remain about durability over 10–15+ years and optimal schedules for higher-risk or immunocompromised populations, where multi-dose schedules are still commonly recommended globally.
Clinical Communication Should Emphasize Strong Evidence Without Overstating Final Certainty
Clinicians can communicate that evidence supports strong protection against HPV16/18 infection outcomes with one dose while acknowledging ongoing durability and policy updates.
This is an exciting shift, but it requires careful messaging: emphasize strong trial evidence on infection endpoints, clarify where guidance differs, and tailor recommendations to patient context.
Centers for Disease Control and Prevention. (n.d.). HPV vaccination recommendations. https://www.cdc.gov/vaccines/vpd/hpv/hcp/recommendations.html
Centers for Disease Control and Prevention. (2026, January 5). CDC acts on presidential memorandum to update childhood immunization schedule [Press release]. https://www.cdc.gov/media/releases/2026/2026-cdc-acts-on-presidential-memorandum-to-update-childhood-immunization-schedule.html
Bénard, É., Drolet, M., Laprise, J.-F., Gingras, G., Jit, M., Boily, M.-C., Bloem, P., & Brisson, M. (2023). Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: A mathematical modelling analysis. The Lancet Public Health, 8(10), e788–e799. https://doi.org/10.1016/S2468-2667(23)00180-9
Kreimer, A. R., Porras, C., Liu, D., Hildesheim, A., Carvajal, L. J., Ocampo, R., … Herrero, R. (2025). Noninferiority of one HPV vaccine dose to two doses. The New England Journal of Medicine, 393(24), 2421–2433. https://doi.org/10.1056/NEJMoa2506765
U.S. Department of Health and Human Services. (2026, January 5). Fact sheet: CDC childhood immunization recommendations. https://www.hhs.gov/press-room/fact-sheet-cdc-childhood-immunization-recommendations.html
World Health Organization. (2022, April 11). One-dose human papillomavirus (HPV) vaccine offers solid protection against cervical cancer. https://www.who.int/news/item/11-04-2022-one-dose-human-papillomavirus-(hpv)-vaccine-offers-solid-protection-against-cervical-cancer
World Health Organization. (2022, December 20). WHO updates recommendations on HPV vaccination schedule. https://www.who.int/news/item/20-12-2022-WHO-updates-recommendations-on-HPV-vaccination-schedule
